Trend Analysis Report: Fairmount Santrol Holdings Inc (NYSE:FMSA), Amicus Therapeutics, Inc. (NASDAQ:FOLD)

On Friday, Shares of Fairmount Santrol Holdings Inc (NYSE:FMSA), SUBTRACT -0.84% and closed at $8.30 in the last trading session. The last trading range of the stock ranges between $7.74 and $8.35. Fairmount Santrol Holdings Inc., together with its auxiliaries, provides sand-based proppant solutions for exploration and production companies to enhance the productivity of their oil and gas wells. The company operates in two segments, Proppant Solutions; and Industrial & Recreational (I&R) Products. The Proppant Solutions segment mainly provides sand-based proppants for use in hydraulic fracturing operations in the United States, Canada, Argentina, Mexico, China, Northern Europe, and the United Arab Emirates. Its products include northern white frac sand, API-spec brown sand, and resin coated proppants, in addition to ceramic proppants; PowerProp product; and Propel SSP product that utilizes a polymer coating applied to a proppant substrate. The I&R Products segment offers raw, coated, and custom blended sands for use in building products, glass, turf and landscape, and filtration industries, in addition to for foundries mainly in North America.

Amicus Therapeutics, Inc. (NASDAQ:FOLD), jumped 3.72% and closed at $9.20 in the last trading session. The last trading range of the stock ranges between $8.54 and $9.22. The company’s Market capitalization is $1.36 Billion with the total Outstanding Shares of 142.33 million. Amicus Therapeutics (FOLD), a global biotechnology company at the forefront of rare and orphan diseases, recently declared that data from the pivotal Phase 3 Study 012 (ATTRACT) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat contrast with Enzyme Replacement Therapy (ERT) in individuals with Fabry disease were published online in the Journal of Medical Genetics1.

“We are honored that the Journal of Medical Genetics has published our pivotal Phase 3 ATTRACT study in patients with Fabry disease who were switched from ERT to migalastat,” said Jay Barth, MD, Chief Medical Officer of Amicus Therapeutics, Inc. “We believe that this 18-month, randomized, active-controlled study generated a strong clinical data set for our precision medicine migalastat. This Phase 3 study, together with our Phase 3 Study 011 in Fabry patients who were naïve to treatment, supported the European Commission’s full approval for migalastat in the European Union as a first line therapy for Fabry disease in patients 16 years and older who have an amfacilitate genetic mutation. This publication is a major accomplishment, and I would like to thank the physicians who were investigators in this study, in addition to the patients and families who take partd in the study.”

Leave a Reply

Your email address will not be published. Required fields are marked *